

Sponsored by: **Biomed Diagnostics**

SgSI Seminar Series: Infectious Diseases

Date & Time: 22 May 2014 (Thursday), 4.30 - 5.45pm *Venue: CeLS Auditorium @ NUS Hosts: Dr Katja Fink, SIgN & Dr Dr. Silvie Alonso, NUS

Registration is based on first-come first-served. Click <u>here</u> to register now!



Dr. Chen Qing Feng Group Leader

IMCB, A*STAR / SMART, ID IRG

Developing humanized mouse models for disease study

Many pathogens that infect humans are highly species specific and are unable to infect other animals. Moreover, over 600 million year evolution, the interaction between the human immune system and pathogens frequently differs from other animal models. Hence, novel in vivo models are required to characterize these human specific pathogens, study human antiinfection responses and evaluate novel drugs and vaccines. We have found that adoptive transfer of human stem cells into immune-deficient mice leads to development of human blood, liver and other cell systems in mice (humanized mouse). These humanized mouse models developed in our lab have allowed the generation of models that enable in vivo studies with pathogens such as HBV, HCV and so on. Our work of the last few years on humanized mouse models has set the scene for the deeper exploration of human immunology and stem cell research and an increasingly prominent place in pre-clinical trials for humanized mice.



Dr. Lisa Ng Principal Investigator SIgN, A*STAR

Cellular and molecular mechanisms of Chikungunya virus pathogenesis: implications for disease interventions

Chikungunya fever has re-emerged as an important human arboviral infection. Sporadic infections are still being reported in many parts of the world, causing severe morbidity with extensive incapacitation in naïve populations. Questions remain about the role of possible microevolution on viral virulence and severity of the associated disease. Importantly, the exact nature of the protective immune defense and the pathogenic mechanisms of debilitating arthralgia and arthritis upon Chikungunya virus (CHIKV) infection are still poorly known. With the increasing spread of the virus around the world, integrated approaches would be essential in order to gather fundamental knowledge on the immune responses mounted against CHIKV. Studies have demonstrated how understanding innate and adaptive immunity against CHIKV could be exploited to develop new immunebased preventive and treatment strategies. These findings will be relevant for the rational design of effective therapies against arthralgia-inducing CHIKV and other re-emerging arthrogenic alphaviruses.

*Address: 28 Medical Drive, Centre for Life Sciences, Level 1, Singapore 117456



This seminar is sponsored by **Biomed Diagnostics**

Seize the Power of the Full Spectrum



eBioscience reagents for multicolor flow cytometry

Quality First. Value Always.

- · Uncompromising Quality antibodies validated in relevant biological systems
- Optimal Performance maximum signal: noise
- Flexible Packaging scalable to study size
- Reliable Reagents dependable lot-to-lot consistency
- Empowering Discovery rapid product development

eBioscience Fluorochrome Choices

Ruorochrome	Excitation Laser	Emission Max. (mm)	Dichroic Mirror	Band Pass Filter
VIOLET LASER:				
efluxr* 450	405, 407	450		440/40, 450/50
eRuar® 605NC	355,405,407	605	595 LP	605/40, 610/20, 605/2
eRuar®625NC	355, 405, 407	625	595 LP	605/50, 625/20
effuar®650NC	355, 405, 407	650	630 LP	655/20, 660/40
BLUE LASER:				
RTC.	488	518	244	530/30
Alexa Flutor® 488	488	519	2.000	530/30
PE	488	575	550 LP	575/26, 585/40
PE-Cy5	488	667	635 LP	670/14, 695/40
PerCP-Cy5.5	488	695	685 LP	695/40, 710/40
PerCP-eFluor® 710	488	710	685 LP	695/40,710/40
PE-CY7	488	785	735 LP	780/60, 780/40
RED LASER:				
APC .	633,635,640	660		660/20
Aleca Fluor® 647	633,635,640	668	842	660/20
Aleca Fluor® 700	633,635,640	723	685 LP	710/40, 710/50, 720/4
APC-eFkuor® 780	633,635,640	780	740 LP	780/60

full spectrum cell analysis*

www.eBioscience.com

Biomed Diagnostics eBioscience